Medications/Drugs (Outpatient/Part B) | UHC Coverage Update

TL;DR: UnitedHealthcare modified its outpatient/Part B medications and drugs coverage policy (medications-drugs-outpatient-partb), effective March 2, 2026. Here's what billing teams need to know about Part B vs. Part D drug routing, DME face-to-face requirements, and self-administered drug exclusions.

UnitedHealthcare updated this Medicare Advantage medical policy governing outpatient drug and biological reimbursement under Part B and Part D. The policy does not list specific CPT or HCPCS codes, but it directly affects any practice billing drugs incident to a physician's service, managing infusion pumps, or prescribing medications that could route to either Part B or Part D. If your team handles oncology, infusion therapy, DME with implantable pumps, or nebulizers, this policy change belongs on your radar before the effective date of March 2, 2026.

---

Quick-Reference Table

Field	Detail Copy
Payer	UnitedHealthcare
Policy	Medications/Drugs (Outpatient/Part B) – Medicare Advantage Medical Policy
Policy Code	medications-drugs-outpatient-partb
Change Type	Modified
Effective Date	March 2, 2026
Impact Level	High
Specialties Affected	Oncology, infusion therapy, pulmonology (nebulizers), DME suppliers, primary care billing incident-to drugs
Key Action	Audit your Part B drug claims for correct routing (Part B vs. Part D) and confirm face-to-face documentation is in place for DME-linked infusion pumps

---

UnitedHealthcare Outpatient Drug Coverage Criteria and Medical Necessity Requirements 2026

The UnitedHealthcare outpatient/Part B medications coverage policy covers drugs billed incident to a physician's service — but only when those drugs are "not usually self-administered by the patient." That phrase is doing a lot of work in this policy, and misreading it is how you generate a claim denial.

The standard is simple: if a drug is generally self-administered, it doesn't qualify for Part B coverage. UnitedHealthcare follows Medicare's own rule here, pulling directly from the Medicare Benefit Policy Manual, Chapter 15, §50. The practical implication is that coverage is mostly limited to drugs administered by infusion or injection in a clinical setting.

There's a named example in the policy that should stop you cold: Imitrex (sumatriptan). Even though it's an injection, UnitedHealthcare explicitly identifies it as generally self-administered and therefore not covered under Part B. If you're billing injectable drugs incident to a service, don't assume "injection" automatically means Part B coverage. Medical necessity alone doesn't carry the claim — the route and the "not usually self-administered" standard both have to be met.

Some self-administered drugs do qualify for Part B coverage. The policy acknowledges specific exceptions, pointing to its own internal "Medications/Drugs Covered Under Part B" reference list. Review that list before assuming any self-administered medication falls outside Part B billing entirely.

DME Face-to-Face Requirement Under Medicare Advantage

Section 6407 of the Affordable Care Act established a face-to-face encounter requirement for certain durable medical equipment. UnitedHealthcare's coverage policy enforces this for four specific device categories: implantable infusion pumps, implantable programmable infusion pumps, external ambulatory infusion pumps, and nebulizers.

The face-to-face requirement also extends to prosthetics, orthotics (non-foot), nutritional therapy, and medical supplies. If your practice orders these items for Medicare Advantage members, the ordering physician needs a documented face-to-face encounter — not just a chart note — before the order is valid for reimbursement. Missing this step is a straightforward route to denial.

Prior authorization requirements for DME-related drugs are not explicitly detailed in this policy update, but the face-to-face rule is a prerequisite that sits upstream of any prior auth request. Get the encounter documented first.

---

UnitedHealthcare Part B vs. Part D Drug Routing — What This Policy Actually Decides

This is where most billing errors live. The UnitedHealthcare Part B medications billing policy draws a hard line: if a drug can be covered under Part A or Part B for a given patient, it cannot be covered under Part D. Full stop.

CMS's interpretation — which UnitedHealthcare follows — is that if Part B payment "could be available" for a drug, Part D is off the table. This is not a gray area. Billing a Part B-eligible drug under Part D is a routing error, and it will come back as a claim denial or, worse, a compliance issue.

Part D coverage applies to drugs that are FDA-approved, available only by prescription, sold in the United States, and used for a medically accepted indication. The policy references two recognized compendia for establishing medically accepted indications: the American Hospital Formulary Service Drug Information and the DRUGDEX® Information System. If a drug's use isn't in one of those two sources — or isn't FDA-approved for that indication — it doesn't meet the Part D definition of a medically accepted indication.

For members with UnitedHealthcare Part D coverage, the policy directs you to the Member's Pharmacy Booklet or Prescription Solutions Customer Service to confirm eligibility. Build that step into your workflow for any medication where Part B eligibility is uncertain.

---

UnitedHealthcare Unlabeled Drug Use — Coverage Policy and Off-Label Criteria 2026

Off-label drug use under Part B is covered — but only under specific conditions. UnitedHealthcare's coverage policy requires that a UnitedHealthcare Medical Director (or designee) determine the use is medically acceptable. That determination draws on major drug compendia, authoritative medical literature, and accepted standards of medical practice.

The standard aligns with Medicare Benefit Policy Manual Chapter 15, §50.4.2. Unlabeled use doesn't get automatic approval. Your clinical team needs to be ready to support the medical necessity argument before the claim goes out the door.

For anti-cancer chemotherapeutic regimens specifically, UnitedHealthcare follows the compendia list from Medicare Benefit Policy Manual Chapter 15, §50.4.5.B. Oncology billing teams should confirm their off-label chemo claims cite the right compendia references. A citation mismatch on an off-label chemo claim is a fixable problem — but only if you catch it before submission.

---

Coverage Indications at a Glance

---

UnitedHealthcare Outpatient Drug Billing Guidelines and Action Items 2026

Copy Action Items

---

CPT, HCPCS, and ICD-10 Codes for Outpatient/Part B Drugs Under medications-drugs-outpatient-partb

This policy does not list specific CPT, HCPCS, or ICD-10 codes. UnitedHealthcare's medications-drugs-outpatient-partb policy governs the coverage framework and routing rules for outpatient drug billing — it does not enumerate individual drug codes or procedure codes within this document.

To identify the specific codes that fall under Part B vs. Part D coverage for your patient population, refer to:

• UnitedHealthcare's internal Medications/Drugs Covered Under Part B reference list (cited within the policy)
• The Medicare Benefit Policy Manual, Chapter 15, §50 for Part B drug coverage criteria
• The Medicare Prescription Drug Benefit Manual, Chapter 6, §10 for Part D drug definitions
• The Medicare Prescription Drug Benefit Manual, Chapter 6, §10.6 for medically accepted indication standards

Your Medicare Administrative Contractor (MAC) may also publish local coverage determinations (LCDs) that affect which specific drugs qualify under Part B for your region. Check your MAC's LCD database alongside this UnitedHealthcare policy — regional variation is real, and the two layers don't always align cleanly.

---